ArticleBMC research notes2025
Distribution of serogroup and pathogenicity Island markers of uropathogenic Escherichia coli from inpatients in a tertiary care hospital.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUropathogenic Escherichia coli (UPEC) are associated with considerable prolonged hospital stay and morbidity worldwide. This work was proposed to study Pathogenicity Island (PAI) markers (as an element containing some important virulence genes) and O-antigen serogroups related to UPECs obtained from inpatients with urinary disorders. This retrospective cross-sectional study was conducted on a total of 126 no repetitive UPEC isolates from three Shiraz teaching hospitals. Isolates were identified using standard microbiological procedures. The PAIs and serogroups genes were screened using PCR.
resultsO-serogroups were identified in 67 (53.1%) of the UPEC isolates. Overall, serotype O25 had the highest incidence (n = 26; 20.8%). Serogroups of O4, O6, O7, O16 and O21 were not detected in our isolates. All of isolates carried at least one of the examined PAI markers. PAI IV536 was the most prevalent PAI (97; 77.6%), followed by PAI II536 (32; 25.6%), PAI III536 (13; 10.4%) and PAI I536 (12; 9.6%). Among serogroups, O25 showed the highest frequency among PAIs.
conclusionThe results of current study enhance the understanding of the importance of serogroups and PAI that could be a beneficial tool for detecting pathogenic UPEC which can be used to develop treatments and prevention strategies for UTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.